Bexagliflozin vs Dapagliflozin

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Type 2 Diabetes

Shared mechanism: SGLT2 · full Type 2 Diabetes pipeline

Bexagliflozin · Brenzavvy

Marketed by Theracos and partners

Approved in Type 2 Diabetessmall molecule
Reliable signal

NCT02558296 · Phase 3 · completed

This was a large randomized, quadruple-blind, placebo-controlled trial with 1,700 participants, and its primary HbA1c comparison at week 24 was statistically significant in favor of bexagliflozin. HbA1c is an approvable primary endpoint in type 2 diabetes, so the design and the result support strong evidence.

Next expected readout: March 2029 · NCT07547878 (registry estimate)

Reported efficacy

Change From Baseline in HbA1c at Week 60 (Baseline and Week 60): Change From Baseline in HbA1c at Week 60 (Baseline and Week 60): Bexagliflozin -0.7 percentage of glycated hemoglin (Standard Error 0.058) vs Glimepiride -0.66 percentage of glycated hemoglin (Standard Error 0.058) (met)

Result source: NCT02769481

Dapagliflozin · Farxiga / Forxiga

Marketed by AstraZeneca and partners

Approved in Type 2 Diabetessmall molecule
Partial signal

NCT00528372 · Phase 3 · completed

The study was randomized, double-blind, placebo-controlled, and included 1,067 enrolled participants, with 558 receiving short-term treatment; its primary HbA1c endpoint is an accepted disease-defining measure for type 2 diabetes. Results were mixed across the primary dose comparisons: 5 mg and 10 mg morning doses significantly outperformed placebo, while 2.5 mg did not, and the exploratory high-baseline-HbA1c group lacked a comparator.

Next expected readout: November 2026 · NCT06954090 (registry estimate)

Reported efficacy

Adjusted Mean Change From Baseline in HbA1c Levels (Baseline to week 24): Adjusted Mean Change From Baseline in HbA1c Levels (Baseline to week 24): Dapagliflozin 10mg Plus Metformin Plus Sulfonylurea -0.86 Percent (95% CI -1 to -0.72) vs Placebo Plus Metformin Plus Sulfonylurea -0.17 Percent (95% CI -0.31 to -0.02) (met)

Result source: NCT01392677

Results for Type 2 Diabetes

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointBexagliflozinDapagliflozin
HbA1c, change-0.8% vs -0.4%−0.5 vs placebo20 mg · wk 24 · n 1046NCT02558296
23 other results
  • -1.1% vs -0.6% 20 mg · wk 24 · n 142 · Phase 3 · primary NCT03259789
  • -0.5% vs -0.1% 20 mg · wk 24 · n 138 · Phase 3 · primary NCT02715258
  • -0.6% vs -0.3% 20 mg · wk 24 · n 157 · Phase 3 · primary NCT02836873
  • -0.7% vs -0.8% wk 24 · n 180 · Phase 3 · primary NCT03115112
  • -0.7% vs -0.7% wk 60 · n 193 · Phase 3 · primary NCT02769481
  • -1.1% vs -0.6% 20 mg · wk 24 · n 158 · Phase 3 · secondary NCT03259789
  • -0.6% vs -0.4% 20 mg · wk 24 · n 86 · Phase 3 · secondary NCT02836873
  • -0.6% vs -0.2% 20 mg · wk 24 · n 71 · Phase 3 · secondary NCT02836873
  • -1% vs -0.5% 20 mg · wk 18 · n 158 · Phase 3 · secondary NCT03259789
  • -1.0% vs -0.3% 20 mg · wk 12 · n 158 · Phase 3 · secondary NCT03259789
  • -0.7% vs -0.2% 20 mg · wk 6 · n 158 · Phase 3 · secondary NCT03259789
  • -0.6% vs 0.2% 20 mg · wk 12 · n 68 · Phase 2 · primary NCT02390050
  • -0.4% vs 0.2% 10 mg · wk 12 · n 68 · Phase 2 · primary NCT02390050
  • -0.3% vs 0.2% 5 mg · wk 12 · n 65 · Phase 2 · primary NCT02390050
  • -0.6% vs 0.2% 20 mg · wk 12 · n 75 · Phase 2 · secondary NCT02390050
  • -0.4% vs 0.1% 20 mg · wk 6 · n 75 · Phase 2 · secondary NCT02390050
  • -0.1% vs 0% 20 mg · wk 2 · n 75 · Phase 2 · secondary NCT02390050
  • -0.4% vs 0.2% 10 mg · wk 12 · n 72 · Phase 2 · secondary NCT02390050
  • -0.4% vs 0.1% 10 mg · wk 6 · n 72 · Phase 2 · secondary NCT02390050
  • -0.1% vs 0% 10 mg · wk 2 · n 72 · Phase 2 · secondary NCT02390050
  • -0.3% vs 0.2% 5 mg · wk 12 · n 71 · Phase 2 · secondary NCT02390050
  • -0.3% vs 0.1% 5 mg · wk 6 · n 71 · Phase 2 · secondary NCT02390050
  • -0.1% vs 0% 5 mg · wk 2 · n 71 · Phase 2 · secondary NCT02390050
-0.9% vs -0.2%−0.7 vs placebo10 mg AM · wk 24 · n 65NCT00528372
50 other results
  • -0.8% vs -0.2% 10 mg PM · wk 24 · n 73 · Phase 3 · primary NCT00528372
  • -0.9% vs -0.2% 10 mg · wk 24 · n 108 · Phase 3 · primary NCT01392677
  • -0.9% vs -0.3% 10mg · wk 24 · n 192 · Phase 3 · primary NCT00673231
  • -0.8% vs -0.3% 5mg · wk 24 · n 210 · Phase 3 · primary NCT00673231
  • -0.8% vs -0.3% 2.5mg · wk 24 · n 198 · Phase 3 · primary NCT00673231
  • -0.6% vs 0.1% 10 mg · wk 12 · n 23 · Phase 2/3 · primary NCT00357370
  • -0.7% vs 0.1% 20 mg · wk 12 · n 23 · Phase 2/3 · primary NCT00357370
  • -0.8% vs -0.2% 5 mg AM · wk 24 · n 61 · Phase 3 · primary NCT00528372
  • -0.8% vs -0.2% 5 mg PM · wk 24 · n 63 · Phase 3 · primary NCT00528372
  • -0.6% vs -0.2% 2.5 mg AM · wk 24 · n 64 · Phase 3 · primary NCT00528372
  • -0.8% vs -0.2% 2.5 mg PM · wk 24 · n 62 · Phase 3 · primary NCT00528372
  • -0.8% vs -0.3% 10 mg · wk 24 · n 132 · Phase 3 · primary NCT00528879
  • -0.8% vs -0.1% 10 mg · wk 24 · n 150 · Phase 3 · primary NCT00680745
  • -1.0% vs -0.4% 10MG · wk 24 · n 140 · Phase 3 · primary NCT00683878
  • -0.7% vs -0.3% 5 mg · wk 24 · n 133 · Phase 3 · primary NCT00528879
  • -0.6% vs -0.1% 5 mg · wk 24 · n 142 · Phase 3 · primary NCT00680745
  • -0.8% vs -0.4% 5MG · wk 24 · n 140 · Phase 3 · primary NCT00683878
  • -0.7% vs -0.3% 2.5 mg · wk 24 · n 135 · Phase 3 · primary NCT00528879
  • -0.6% vs -0.1% 2.5 mg · wk 24 · n 154 · Phase 3 · primary NCT00680745
  • -0.5% vs 0.0% wk 24 · n 223 · Phase 3 · primary NCT00984867
  • -0.6% vs 0.4% wk 26 · n 75 · Phase 3 · primary NCT03199053
  • -1.2% vs -1.4% 5 mg · wk 24 · n 196 · Phase 3 · primary NCT00643851
  • -2.0% vs -1.4% wk 24 · n 185 · Phase 3 · primary NCT00643851
  • -2.0% vs -1.4% wk 24 · n 202 · Phase 3 · primary NCT00859898
  • -1.4% vs -1.4% wk 24 · n 216 · Phase 3 · primary NCT00859898
  • -0.5% vs -0.5% wk 52 · n 400 · Phase 3 · primary NCT00660907
  • -0.9% vs -0.2% 10 mg AM · wk 24 · n 59 · Phase 3 · secondary NCT00528372
  • -0.8% vs -0.2% 10 mg PM · wk 24 · n 60 · Phase 3 · secondary NCT00528372
  • -0.7% vs -0.2% 5 mg AM · wk 24 · n 53 · Phase 3 · secondary NCT00528372
  • -0.8% vs -0.2% 5 mg PM · wk 24 · n 54 · Phase 3 · secondary NCT00528372
  • -0.6% vs -0.2% 2.5 mg AM · wk 24 · n 53 · Phase 3 · secondary NCT00528372
  • -0.8% vs -0.2% 2.5 mg PM · wk 24 · n 48 · Phase 3 · secondary NCT00528372
  • -0.9% vs -0.3% 10 mg · wk 24 · n 104 · Phase 3 · secondary NCT00528879
  • -0.7% vs -0.3% 5 mg · wk 24 · n 109 · Phase 3 · secondary NCT00528879
  • -0.7% vs -0.3% 2.5 mg · wk 24 · n 118 · Phase 3 · secondary NCT00528879
  • -2.0% vs 0.2% 10 mg AM · wk 24 · n 14 · Phase 3 · secondary NCT00528372
  • -1.2% vs 0.2% 10 mg PM · wk 24 · n 12 · Phase 3 · secondary NCT00528372
  • -1.4% vs -0.5% 5 mg · wk 24 · n 34 · Phase 3 · secondary NCT00528879
  • -0.8% vs 0.0% wk 24 · n 94 · Phase 3 · secondary NCT00984867
  • -2% vs 0.2% 5 mg AM · wk 24 · n 9 · Phase 3 · secondary NCT00528372
  • -1.5% vs 0.2% 5 mg PM · wk 24 · n 8 · Phase 3 · secondary NCT00528372
  • -1.3% vs 0.2% 2.5 mg AM · wk 24 · n 8 · Phase 3 · secondary NCT00528372
  • -1.4% vs 0.2% 2.5 mg PM · wk 24 · n 11 · Phase 3 · secondary NCT00528372
  • -1.3% vs -0.5% 10 mg · wk 24 · n 18 · Phase 3 · secondary NCT00528879
  • -1.2% vs -0.5% 2.5 mg · wk 24 · n 17 · Phase 3 · secondary NCT00528879
  • -1.7% vs -1.8% 5 mg · wk 24 · n 96 · Phase 3 · secondary NCT00643851
  • -3.0% vs -1.8% wk 24 · n 92 · Phase 3 · secondary NCT00643851
  • -2.6% vs -2.0% wk 24 · n 106 · Phase 3 · secondary NCT00859898
  • -2.1% vs -2.0% wk 24 · n 97 · Phase 3 · secondary NCT00859898
  • -1% vs -0.5% wk 52 · n 56 · Phase 4 · secondary NCT02564926
Body weight, change (kg)-3.0 vs -0.4−2.6 vs placebo20 mg · wk 48 · n 922NCT02558296
14 other results
  • -3.6 vs -1.1 20 mg · wk 24 · n 119 · Phase 3 · secondary NCT03259789
  • -1.9 vs -1.1 20 mg · wk 24 · n 128 · Phase 3 · secondary NCT02715258
  • -2.3 vs -0.6 20 mg · wk 24 · n 122 · Phase 3 · secondary NCT02836873
  • -3.4 vs -0.8 wk 24 · n 158 · Phase 3 · secondary NCT03115112
  • -3.7 vs 0.6 wk 60 · n 182 · Phase 3 · secondary NCT02769481
  • -1.9 vs -0.1 20 mg · wk 12 · n 75 · Phase 2 · secondary NCT02390050
  • -1.5 vs 0.0 20 mg · wk 6 · n 75 · Phase 2 · secondary NCT02390050
  • -1.0 vs 0 20 mg · wk 2 · n 75 · Phase 2 · secondary NCT02390050
  • -1.7 vs -0.1 10 mg · wk 12 · n 72 · Phase 2 · secondary NCT02390050
  • -1.4 vs 0.0 10 mg · wk 6 · n 72 · Phase 2 · secondary NCT02390050
  • -0.8 vs 0 10 mg · wk 2 · n 72 · Phase 2 · secondary NCT02390050
  • -1.6 vs -0.1 5 mg · wk 12 · n 71 · Phase 2 · secondary NCT02390050
  • -1 vs 0.0 5 mg · wk 6 · n 71 · Phase 2 · secondary NCT02390050
  • -0.7 vs 0 5 mg · wk 2 · n 71 · Phase 2 · secondary NCT02390050
-3.2 vs -2.2−1 vs placebo10 mg AM · wk 24 · n 69NCT00528372
40 other results
  • -3.0 vs -2.2 10 mg PM · wk 24 · n 74 · Phase 3 · secondary NCT00528372
  • -3.4 vs -2.4 10 mg AM · wk 24 · n 63 · Phase 3 · secondary NCT00528372
  • -3.4 vs -2.4 10 mg PM · wk 24 · n 61 · Phase 3 · secondary NCT00528372
  • -2.6 vs -0.6 10 mg · wk 24 · n 108 · Phase 3 · secondary NCT01392677
  • -1.7 vs 0.0 10mg · wk 24 · n 192 · Phase 3 · secondary NCT00673231
  • -1.0 vs 0.0 5mg · wk 24 · n 210 · Phase 3 · secondary NCT00673231
  • -1.0 vs 0.0 2.5mg · wk 24 · n 198 · Phase 3 · secondary NCT00673231
  • -2.8 vs -2.2 5 mg AM · wk 24 · n 62 · Phase 3 · secondary NCT00528372
  • -3.5 vs -2.2 5 mg PM · wk 24 · n 66 · Phase 3 · secondary NCT00528372
  • -2.9 vs -2.4 5 mg AM · wk 24 · n 54 · Phase 3 · secondary NCT00528372
  • -3.7 vs -2.4 5 mg PM · wk 24 · n 57 · Phase 3 · secondary NCT00528372
  • -3.3 vs -2.2 2.5 mg AM · wk 24 · n 65 · Phase 3 · secondary NCT00528372
  • -3.8 vs -2.2 2.5 mg PM · wk 24 · n 67 · Phase 3 · secondary NCT00528372
  • -3.4 vs -2.4 2.5 mg AM · wk 24 · n 54 · Phase 3 · secondary NCT00528372
  • -4.3 vs -2.4 2.5 mg PM · wk 24 · n 53 · Phase 3 · secondary NCT00528372
  • -2.9 vs -0.9 10 mg · wk 24 · n 133 · Phase 3 · secondary NCT00528879
  • -3.1 vs -1.0 10 mg · wk 24 · n 108 · Phase 3 · secondary NCT00528879
  • -2.3 vs -0.7 10 mg · wk 24 · n 151 · Phase 3 · secondary NCT00680745
  • -2.5 vs -0.8 10 mg · wk 24 · n 99 · Phase 3 · secondary NCT00680745
  • -0.1 vs 1.6 10MG · wk 24 · n 140 · Phase 3 · secondary NCT00683878
  • -0.1 vs 1.8 10MG · wk 24 · n 113 · Phase 3 · secondary NCT00683878
  • -3.0 vs -0.9 5 mg · wk 24 · n 137 · Phase 3 · secondary NCT00528879
  • -3.2 vs -1.0 5 mg · wk 24 · n 111 · Phase 3 · secondary NCT00528879
  • -1.6 vs -0.7 5 mg · wk 24 · n 142 · Phase 3 · secondary NCT00680745
  • -1.7 vs -0.8 5 mg · wk 24 · n 97 · Phase 3 · secondary NCT00680745
  • 0.1 vs 1.6 5MG · wk 24 · n 140 · Phase 3 · secondary NCT00683878
  • 0.3 vs 1.8 5MG · wk 24 · n 101 · Phase 3 · secondary NCT00683878
  • -2.2 vs -0.9 2.5 mg · wk 24 · n 137 · Phase 3 · secondary NCT00528879
  • -2.4 vs -1.0 2.5 mg · wk 24 · n 120 · Phase 3 · secondary NCT00528879
  • -1.2 vs -0.7 2.5 mg · wk 24 · n 154 · Phase 3 · secondary NCT00680745
  • -1.2 vs -0.8 2.5 mg · wk 24 · n 104 · Phase 3 · secondary NCT00680745
  • -2.1 vs -0.3 wk 24 · n 223 · Phase 3 · secondary NCT00984867
  • -2.6 vs -1.3 5 mg · wk 24 · n 203 · Phase 3 · secondary NCT00643851
  • -2.9 vs -1.5 5 mg · wk 24 · n 156 · Phase 3 · secondary NCT00643851
  • -2.7 vs -1.3 wk 24 · n 192 · Phase 3 · secondary NCT00643851
  • -3.0 vs -1.5 wk 24 · n 142 · Phase 3 · secondary NCT00643851
  • -3.3 vs -1.4 wk 24 · n 209 · Phase 3 · secondary NCT00859898
  • -2.7 vs -1.4 wk 24 · n 219 · Phase 3 · secondary NCT00859898
  • -3.2 vs 1.4 wk 52 · n 400 · Phase 3 · secondary NCT00660907
  • -2.4 vs 1.3 wk 52 · n 56 · Phase 4 · secondary NCT02564926
HbA1c below 7%—Not reported50.8% vs 31.6%+19.2 vs placebo10 mg AM · wk 24 · n 65NCT00528372
17 other results
  • 51.6% vs 31.6% 10 mg PM · wk 24 · n 73 · Phase 3 · secondary NCT00528372
  • 31.8% vs 11.1% 10 mg · wk 24 · n 108 · Phase 3 · secondary NCT01392677
  • 44.2% vs 31.6% 5 mg AM · wk 24 · n 61 · Phase 3 · secondary NCT00528372
  • 44% vs 31.6% 5 mg PM · wk 24 · n 63 · Phase 3 · secondary NCT00528372
  • 41.3% vs 31.6% 2.5 mg AM · wk 24 · n 64 · Phase 3 · secondary NCT00528372
  • 51.4% vs 31.6% 2.5 mg PM · wk 24 · n 62 · Phase 3 · secondary NCT00528372
  • 40.6% vs 25.9% 10 mg · wk 24 · n 132 · Phase 3 · secondary NCT00528879
  • 31.7% vs 13% 10 mg · wk 24 · n 150 · Phase 3 · secondary NCT00680745
  • 38.8% vs 22.4% 10MG · wk 24 · n 140 · Phase 3 · secondary NCT00683878
  • 37.5% vs 25.9% 5 mg · wk 24 · n 133 · Phase 3 · secondary NCT00528879
  • 30.3% vs 13% 5 mg · wk 24 · n 142 · Phase 3 · secondary NCT00680745
  • 32.5% vs 22.4% 5MG · wk 24 · n 140 · Phase 3 · secondary NCT00683878
  • 33% vs 25.9% 2.5 mg · wk 24 · n 135 · Phase 3 · secondary NCT00528879
  • 26.8% vs 13% 2.5 mg · wk 24 · n 154 · Phase 3 · secondary NCT00680745
  • 26.6% vs 10% wk 26 · n 64 · Phase 3 · secondary NCT03199053
  • 22.5% vs 34.6% 5 mg · wk 24 · n 196 · Phase 3 · secondary NCT00643851
  • 52.4% vs 34.6% wk 24 · n 185 · Phase 3 · secondary NCT00643851
Fasting plasma glucose, change-2.5 vs -1.2−1.3 vs placebo20 mg · wk 24 · n 142NCT03259789
10 other results
  • -1.8 vs -1.4 wk 24 · n 180 · Phase 3 · secondary NCT03115112
  • -1.2 vs -0.1 20 mg · wk 12 · n 75 · Phase 2 · secondary NCT02390050
  • -1.0 vs 0.1 20 mg · wk 6 · n 75 · Phase 2 · secondary NCT02390050
  • -1.1 vs -0.1 20 mg · wk 2 · n 75 · Phase 2 · secondary NCT02390050
  • -1.2 vs -0.1 10 mg · wk 12 · n 72 · Phase 2 · secondary NCT02390050
  • -1.1 vs 0.1 10 mg · wk 6 · n 72 · Phase 2 · secondary NCT02390050
  • -1.0 vs -0.1 10 mg · wk 2 · n 72 · Phase 2 · secondary NCT02390050
  • -1.0 vs -0.1 5 mg · wk 12 · n 71 · Phase 2 · secondary NCT02390050
  • -0.8 vs 0.1 5 mg · wk 6 · n 71 · Phase 2 · secondary NCT02390050
  • -0.6 vs -0.1 5 mg · wk 2 · n 71 · Phase 2 · secondary NCT02390050
-1.3 vs 0.2−1.5 vs placebowk 24 · n 222NCT00984867
34 other results
  • -1.6 vs -0.2 10 mg AM · wk 24 · n 70 · Phase 3 · secondary NCT00528372
  • -1.6 vs -0.2 10 mg PM · wk 24 · n 73 · Phase 3 · secondary NCT00528372
  • -1.9 vs -0.0 10 mg · wk 24 · n 108 · Phase 3 · secondary NCT01392677
  • -1.2 vs 0.2 10mg · wk 24 · n 183 · Phase 3 · secondary NCT00673231
  • -1.0 vs 0.2 5mg · wk 24 · n 204 · Phase 3 · secondary NCT00673231
  • 0.1 vs 1.0 10 mg · wk 12 · n 23 · Phase 2/3 · secondary NCT00357370
  • -0.9 vs -0.1 10 mg AM · wk 1 · n 65 · Phase 3 · secondary NCT00528372
  • -0.7 vs 0.2 2.5mg · wk 24 · n 190 · Phase 3 · secondary NCT00673231
  • -1.1 vs -0.1 10 mg PM · wk 1 · n 60 · Phase 3 · secondary NCT00528372
  • -0.5 vs 1.0 20 mg · wk 12 · n 23 · Phase 2/3 · secondary NCT00357370
  • -1.3 vs -0.2 5 mg AM · wk 24 · n 64 · Phase 3 · secondary NCT00528372
  • -1.5 vs -0.2 5 mg PM · wk 24 · n 66 · Phase 3 · secondary NCT00528372
  • -0.9 vs -0.1 5 mg AM · wk 1 · n 56 · Phase 3 · secondary NCT00528372
  • -1.0 vs -0.1 5 mg PM · wk 1 · n 54 · Phase 3 · secondary NCT00528372
  • -0.8 vs -0.2 2.5 mg AM · wk 24 · n 65 · Phase 3 · secondary NCT00528372
  • -1.4 vs -0.2 2.5 mg PM · wk 24 · n 67 · Phase 3 · secondary NCT00528372
  • -0.2 vs -0.1 2.5 mg AM · wk 1 · n 57 · Phase 3 · secondary NCT00528372
  • -1.6 vs -0.1 10 mg · wk 24 · n 150 · Phase 3 · secondary NCT00680745
  • -0.8 vs -0.1 2.5 mg PM · wk 1 · n 48 · Phase 3 · secondary NCT00528372
  • -1.3 vs -0.3 10 mg · wk 24 · n 132 · Phase 3 · secondary NCT00528879
  • -1.6 vs -0.3 10MG · wk 24 · n 140 · Phase 3 · secondary NCT00683878
  • -0.9 vs 0.1 10 mg · wk 1 · n 115 · Phase 3 · secondary NCT00528879
  • -1.2 vs -0.3 5 mg · wk 24 · n 136 · Phase 3 · secondary NCT00528879
  • -1.2 vs -0.1 5 mg · wk 24 · n 142 · Phase 3 · secondary NCT00680745
  • -1.4 vs -0.3 5MG · wk 24 · n 140 · Phase 3 · secondary NCT00683878
  • -0.7 vs 0.1 5 mg · wk 1 · n 121 · Phase 3 · secondary NCT00528879
  • -1.0 vs -0.3 2.5 mg · wk 24 · n 137 · Phase 3 · secondary NCT00528879
  • -0.9 vs -0.1 2.5 mg · wk 24 · n 154 · Phase 3 · secondary NCT00680745
  • -0.3 vs 0.1 2.5 mg · wk 1 · n 120 · Phase 3 · secondary NCT00528879
  • -0.6 vs 0.5 wk 26 · n 75 · Phase 3 · secondary NCT03199053
  • -2.3 vs -1.9 5 mg · wk 24 · n 203 · Phase 3 · secondary NCT00643851
  • -3.4 vs -1.9 wk 24 · n 192 · Phase 3 · secondary NCT00643851
  • -3.4 vs -1.9 wk 24 · n 209 · Phase 3 · secondary NCT00859898
  • -2.6 vs -1.9 wk 24 · n 216 · Phase 3 · secondary NCT00859898
3-point MACE (% with event)—Not reported—Not posted · NCT04170998

HbA1c, change

Bexagliflozin
-0.8% vs -0.4%−0.5 vs placebo20 mg · wk 24 · n 1046NCT02558296
23 other results
  • -1.1% vs -0.6% 20 mg · wk 24 · n 142 · Phase 3 · primary NCT03259789
  • -0.5% vs -0.1% 20 mg · wk 24 · n 138 · Phase 3 · primary NCT02715258
  • -0.6% vs -0.3% 20 mg · wk 24 · n 157 · Phase 3 · primary NCT02836873
  • -0.7% vs -0.8% wk 24 · n 180 · Phase 3 · primary NCT03115112
  • -0.7% vs -0.7% wk 60 · n 193 · Phase 3 · primary NCT02769481
  • -1.1% vs -0.6% 20 mg · wk 24 · n 158 · Phase 3 · secondary NCT03259789
  • -0.6% vs -0.4% 20 mg · wk 24 · n 86 · Phase 3 · secondary NCT02836873
  • -0.6% vs -0.2% 20 mg · wk 24 · n 71 · Phase 3 · secondary NCT02836873
  • -1% vs -0.5% 20 mg · wk 18 · n 158 · Phase 3 · secondary NCT03259789
  • -1.0% vs -0.3% 20 mg · wk 12 · n 158 · Phase 3 · secondary NCT03259789
  • -0.7% vs -0.2% 20 mg · wk 6 · n 158 · Phase 3 · secondary NCT03259789
  • -0.6% vs 0.2% 20 mg · wk 12 · n 68 · Phase 2 · primary NCT02390050
  • -0.4% vs 0.2% 10 mg · wk 12 · n 68 · Phase 2 · primary NCT02390050
  • -0.3% vs 0.2% 5 mg · wk 12 · n 65 · Phase 2 · primary NCT02390050
  • -0.6% vs 0.2% 20 mg · wk 12 · n 75 · Phase 2 · secondary NCT02390050
  • -0.4% vs 0.1% 20 mg · wk 6 · n 75 · Phase 2 · secondary NCT02390050
  • -0.1% vs 0% 20 mg · wk 2 · n 75 · Phase 2 · secondary NCT02390050
  • -0.4% vs 0.2% 10 mg · wk 12 · n 72 · Phase 2 · secondary NCT02390050
  • -0.4% vs 0.1% 10 mg · wk 6 · n 72 · Phase 2 · secondary NCT02390050
  • -0.1% vs 0% 10 mg · wk 2 · n 72 · Phase 2 · secondary NCT02390050
  • -0.3% vs 0.2% 5 mg · wk 12 · n 71 · Phase 2 · secondary NCT02390050
  • -0.3% vs 0.1% 5 mg · wk 6 · n 71 · Phase 2 · secondary NCT02390050
  • -0.1% vs 0% 5 mg · wk 2 · n 71 · Phase 2 · secondary NCT02390050
Dapagliflozin
-0.9% vs -0.2%−0.7 vs placebo10 mg AM · wk 24 · n 65NCT00528372
50 other results
  • -0.8% vs -0.2% 10 mg PM · wk 24 · n 73 · Phase 3 · primary NCT00528372
  • -0.9% vs -0.2% 10 mg · wk 24 · n 108 · Phase 3 · primary NCT01392677
  • -0.9% vs -0.3% 10mg · wk 24 · n 192 · Phase 3 · primary NCT00673231
  • -0.8% vs -0.3% 5mg · wk 24 · n 210 · Phase 3 · primary NCT00673231
  • -0.8% vs -0.3% 2.5mg · wk 24 · n 198 · Phase 3 · primary NCT00673231
  • -0.6% vs 0.1% 10 mg · wk 12 · n 23 · Phase 2/3 · primary NCT00357370
  • -0.7% vs 0.1% 20 mg · wk 12 · n 23 · Phase 2/3 · primary NCT00357370
  • -0.8% vs -0.2% 5 mg AM · wk 24 · n 61 · Phase 3 · primary NCT00528372
  • -0.8% vs -0.2% 5 mg PM · wk 24 · n 63 · Phase 3 · primary NCT00528372
  • -0.6% vs -0.2% 2.5 mg AM · wk 24 · n 64 · Phase 3 · primary NCT00528372
  • -0.8% vs -0.2% 2.5 mg PM · wk 24 · n 62 · Phase 3 · primary NCT00528372
  • -0.8% vs -0.3% 10 mg · wk 24 · n 132 · Phase 3 · primary NCT00528879
  • -0.8% vs -0.1% 10 mg · wk 24 · n 150 · Phase 3 · primary NCT00680745
  • -1.0% vs -0.4% 10MG · wk 24 · n 140 · Phase 3 · primary NCT00683878
  • -0.7% vs -0.3% 5 mg · wk 24 · n 133 · Phase 3 · primary NCT00528879
  • -0.6% vs -0.1% 5 mg · wk 24 · n 142 · Phase 3 · primary NCT00680745
  • -0.8% vs -0.4% 5MG · wk 24 · n 140 · Phase 3 · primary NCT00683878
  • -0.7% vs -0.3% 2.5 mg · wk 24 · n 135 · Phase 3 · primary NCT00528879
  • -0.6% vs -0.1% 2.5 mg · wk 24 · n 154 · Phase 3 · primary NCT00680745
  • -0.5% vs 0.0% wk 24 · n 223 · Phase 3 · primary NCT00984867
  • -0.6% vs 0.4% wk 26 · n 75 · Phase 3 · primary NCT03199053
  • -1.2% vs -1.4% 5 mg · wk 24 · n 196 · Phase 3 · primary NCT00643851
  • -2.0% vs -1.4% wk 24 · n 185 · Phase 3 · primary NCT00643851
  • -2.0% vs -1.4% wk 24 · n 202 · Phase 3 · primary NCT00859898
  • -1.4% vs -1.4% wk 24 · n 216 · Phase 3 · primary NCT00859898
  • -0.5% vs -0.5% wk 52 · n 400 · Phase 3 · primary NCT00660907
  • -0.9% vs -0.2% 10 mg AM · wk 24 · n 59 · Phase 3 · secondary NCT00528372
  • -0.8% vs -0.2% 10 mg PM · wk 24 · n 60 · Phase 3 · secondary NCT00528372
  • -0.7% vs -0.2% 5 mg AM · wk 24 · n 53 · Phase 3 · secondary NCT00528372
  • -0.8% vs -0.2% 5 mg PM · wk 24 · n 54 · Phase 3 · secondary NCT00528372
  • -0.6% vs -0.2% 2.5 mg AM · wk 24 · n 53 · Phase 3 · secondary NCT00528372
  • -0.8% vs -0.2% 2.5 mg PM · wk 24 · n 48 · Phase 3 · secondary NCT00528372
  • -0.9% vs -0.3% 10 mg · wk 24 · n 104 · Phase 3 · secondary NCT00528879
  • -0.7% vs -0.3% 5 mg · wk 24 · n 109 · Phase 3 · secondary NCT00528879
  • -0.7% vs -0.3% 2.5 mg · wk 24 · n 118 · Phase 3 · secondary NCT00528879
  • -2.0% vs 0.2% 10 mg AM · wk 24 · n 14 · Phase 3 · secondary NCT00528372
  • -1.2% vs 0.2% 10 mg PM · wk 24 · n 12 · Phase 3 · secondary NCT00528372
  • -1.4% vs -0.5% 5 mg · wk 24 · n 34 · Phase 3 · secondary NCT00528879
  • -0.8% vs 0.0% wk 24 · n 94 · Phase 3 · secondary NCT00984867
  • -2% vs 0.2% 5 mg AM · wk 24 · n 9 · Phase 3 · secondary NCT00528372
  • -1.5% vs 0.2% 5 mg PM · wk 24 · n 8 · Phase 3 · secondary NCT00528372
  • -1.3% vs 0.2% 2.5 mg AM · wk 24 · n 8 · Phase 3 · secondary NCT00528372
  • -1.4% vs 0.2% 2.5 mg PM · wk 24 · n 11 · Phase 3 · secondary NCT00528372
  • -1.3% vs -0.5% 10 mg · wk 24 · n 18 · Phase 3 · secondary NCT00528879
  • -1.2% vs -0.5% 2.5 mg · wk 24 · n 17 · Phase 3 · secondary NCT00528879
  • -1.7% vs -1.8% 5 mg · wk 24 · n 96 · Phase 3 · secondary NCT00643851
  • -3.0% vs -1.8% wk 24 · n 92 · Phase 3 · secondary NCT00643851
  • -2.6% vs -2.0% wk 24 · n 106 · Phase 3 · secondary NCT00859898
  • -2.1% vs -2.0% wk 24 · n 97 · Phase 3 · secondary NCT00859898
  • -1% vs -0.5% wk 52 · n 56 · Phase 4 · secondary NCT02564926

Body weight, change (kg)

Bexagliflozin
-3.0 vs -0.4−2.6 vs placebo20 mg · wk 48 · n 922NCT02558296
14 other results
  • -3.6 vs -1.1 20 mg · wk 24 · n 119 · Phase 3 · secondary NCT03259789
  • -1.9 vs -1.1 20 mg · wk 24 · n 128 · Phase 3 · secondary NCT02715258
  • -2.3 vs -0.6 20 mg · wk 24 · n 122 · Phase 3 · secondary NCT02836873
  • -3.4 vs -0.8 wk 24 · n 158 · Phase 3 · secondary NCT03115112
  • -3.7 vs 0.6 wk 60 · n 182 · Phase 3 · secondary NCT02769481
  • -1.9 vs -0.1 20 mg · wk 12 · n 75 · Phase 2 · secondary NCT02390050
  • -1.5 vs 0.0 20 mg · wk 6 · n 75 · Phase 2 · secondary NCT02390050
  • -1.0 vs 0 20 mg · wk 2 · n 75 · Phase 2 · secondary NCT02390050
  • -1.7 vs -0.1 10 mg · wk 12 · n 72 · Phase 2 · secondary NCT02390050
  • -1.4 vs 0.0 10 mg · wk 6 · n 72 · Phase 2 · secondary NCT02390050
  • -0.8 vs 0 10 mg · wk 2 · n 72 · Phase 2 · secondary NCT02390050
  • -1.6 vs -0.1 5 mg · wk 12 · n 71 · Phase 2 · secondary NCT02390050
  • -1 vs 0.0 5 mg · wk 6 · n 71 · Phase 2 · secondary NCT02390050
  • -0.7 vs 0 5 mg · wk 2 · n 71 · Phase 2 · secondary NCT02390050
Dapagliflozin
-3.2 vs -2.2−1 vs placebo10 mg AM · wk 24 · n 69NCT00528372
40 other results
  • -3.0 vs -2.2 10 mg PM · wk 24 · n 74 · Phase 3 · secondary NCT00528372
  • -3.4 vs -2.4 10 mg AM · wk 24 · n 63 · Phase 3 · secondary NCT00528372
  • -3.4 vs -2.4 10 mg PM · wk 24 · n 61 · Phase 3 · secondary NCT00528372
  • -2.6 vs -0.6 10 mg · wk 24 · n 108 · Phase 3 · secondary NCT01392677
  • -1.7 vs 0.0 10mg · wk 24 · n 192 · Phase 3 · secondary NCT00673231
  • -1.0 vs 0.0 5mg · wk 24 · n 210 · Phase 3 · secondary NCT00673231
  • -1.0 vs 0.0 2.5mg · wk 24 · n 198 · Phase 3 · secondary NCT00673231
  • -2.8 vs -2.2 5 mg AM · wk 24 · n 62 · Phase 3 · secondary NCT00528372
  • -3.5 vs -2.2 5 mg PM · wk 24 · n 66 · Phase 3 · secondary NCT00528372
  • -2.9 vs -2.4 5 mg AM · wk 24 · n 54 · Phase 3 · secondary NCT00528372
  • -3.7 vs -2.4 5 mg PM · wk 24 · n 57 · Phase 3 · secondary NCT00528372
  • -3.3 vs -2.2 2.5 mg AM · wk 24 · n 65 · Phase 3 · secondary NCT00528372
  • -3.8 vs -2.2 2.5 mg PM · wk 24 · n 67 · Phase 3 · secondary NCT00528372
  • -3.4 vs -2.4 2.5 mg AM · wk 24 · n 54 · Phase 3 · secondary NCT00528372
  • -4.3 vs -2.4 2.5 mg PM · wk 24 · n 53 · Phase 3 · secondary NCT00528372
  • -2.9 vs -0.9 10 mg · wk 24 · n 133 · Phase 3 · secondary NCT00528879
  • -3.1 vs -1.0 10 mg · wk 24 · n 108 · Phase 3 · secondary NCT00528879
  • -2.3 vs -0.7 10 mg · wk 24 · n 151 · Phase 3 · secondary NCT00680745
  • -2.5 vs -0.8 10 mg · wk 24 · n 99 · Phase 3 · secondary NCT00680745
  • -0.1 vs 1.6 10MG · wk 24 · n 140 · Phase 3 · secondary NCT00683878
  • -0.1 vs 1.8 10MG · wk 24 · n 113 · Phase 3 · secondary NCT00683878
  • -3.0 vs -0.9 5 mg · wk 24 · n 137 · Phase 3 · secondary NCT00528879
  • -3.2 vs -1.0 5 mg · wk 24 · n 111 · Phase 3 · secondary NCT00528879
  • -1.6 vs -0.7 5 mg · wk 24 · n 142 · Phase 3 · secondary NCT00680745
  • -1.7 vs -0.8 5 mg · wk 24 · n 97 · Phase 3 · secondary NCT00680745
  • 0.1 vs 1.6 5MG · wk 24 · n 140 · Phase 3 · secondary NCT00683878
  • 0.3 vs 1.8 5MG · wk 24 · n 101 · Phase 3 · secondary NCT00683878
  • -2.2 vs -0.9 2.5 mg · wk 24 · n 137 · Phase 3 · secondary NCT00528879
  • -2.4 vs -1.0 2.5 mg · wk 24 · n 120 · Phase 3 · secondary NCT00528879
  • -1.2 vs -0.7 2.5 mg · wk 24 · n 154 · Phase 3 · secondary NCT00680745
  • -1.2 vs -0.8 2.5 mg · wk 24 · n 104 · Phase 3 · secondary NCT00680745
  • -2.1 vs -0.3 wk 24 · n 223 · Phase 3 · secondary NCT00984867
  • -2.6 vs -1.3 5 mg · wk 24 · n 203 · Phase 3 · secondary NCT00643851
  • -2.9 vs -1.5 5 mg · wk 24 · n 156 · Phase 3 · secondary NCT00643851
  • -2.7 vs -1.3 wk 24 · n 192 · Phase 3 · secondary NCT00643851
  • -3.0 vs -1.5 wk 24 · n 142 · Phase 3 · secondary NCT00643851
  • -3.3 vs -1.4 wk 24 · n 209 · Phase 3 · secondary NCT00859898
  • -2.7 vs -1.4 wk 24 · n 219 · Phase 3 · secondary NCT00859898
  • -3.2 vs 1.4 wk 52 · n 400 · Phase 3 · secondary NCT00660907
  • -2.4 vs 1.3 wk 52 · n 56 · Phase 4 · secondary NCT02564926

HbA1c below 7%

Bexagliflozin
—Not reported
Dapagliflozin
50.8% vs 31.6%+19.2 vs placebo10 mg AM · wk 24 · n 65NCT00528372
17 other results
  • 51.6% vs 31.6% 10 mg PM · wk 24 · n 73 · Phase 3 · secondary NCT00528372
  • 31.8% vs 11.1% 10 mg · wk 24 · n 108 · Phase 3 · secondary NCT01392677
  • 44.2% vs 31.6% 5 mg AM · wk 24 · n 61 · Phase 3 · secondary NCT00528372
  • 44% vs 31.6% 5 mg PM · wk 24 · n 63 · Phase 3 · secondary NCT00528372
  • 41.3% vs 31.6% 2.5 mg AM · wk 24 · n 64 · Phase 3 · secondary NCT00528372
  • 51.4% vs 31.6% 2.5 mg PM · wk 24 · n 62 · Phase 3 · secondary NCT00528372
  • 40.6% vs 25.9% 10 mg · wk 24 · n 132 · Phase 3 · secondary NCT00528879
  • 31.7% vs 13% 10 mg · wk 24 · n 150 · Phase 3 · secondary NCT00680745
  • 38.8% vs 22.4% 10MG · wk 24 · n 140 · Phase 3 · secondary NCT00683878
  • 37.5% vs 25.9% 5 mg · wk 24 · n 133 · Phase 3 · secondary NCT00528879
  • 30.3% vs 13% 5 mg · wk 24 · n 142 · Phase 3 · secondary NCT00680745
  • 32.5% vs 22.4% 5MG · wk 24 · n 140 · Phase 3 · secondary NCT00683878
  • 33% vs 25.9% 2.5 mg · wk 24 · n 135 · Phase 3 · secondary NCT00528879
  • 26.8% vs 13% 2.5 mg · wk 24 · n 154 · Phase 3 · secondary NCT00680745
  • 26.6% vs 10% wk 26 · n 64 · Phase 3 · secondary NCT03199053
  • 22.5% vs 34.6% 5 mg · wk 24 · n 196 · Phase 3 · secondary NCT00643851
  • 52.4% vs 34.6% wk 24 · n 185 · Phase 3 · secondary NCT00643851

Fasting plasma glucose, change

Bexagliflozin
-2.5 vs -1.2−1.3 vs placebo20 mg · wk 24 · n 142NCT03259789
10 other results
  • -1.8 vs -1.4 wk 24 · n 180 · Phase 3 · secondary NCT03115112
  • -1.2 vs -0.1 20 mg · wk 12 · n 75 · Phase 2 · secondary NCT02390050
  • -1.0 vs 0.1 20 mg · wk 6 · n 75 · Phase 2 · secondary NCT02390050
  • -1.1 vs -0.1 20 mg · wk 2 · n 75 · Phase 2 · secondary NCT02390050
  • -1.2 vs -0.1 10 mg · wk 12 · n 72 · Phase 2 · secondary NCT02390050
  • -1.1 vs 0.1 10 mg · wk 6 · n 72 · Phase 2 · secondary NCT02390050
  • -1.0 vs -0.1 10 mg · wk 2 · n 72 · Phase 2 · secondary NCT02390050
  • -1.0 vs -0.1 5 mg · wk 12 · n 71 · Phase 2 · secondary NCT02390050
  • -0.8 vs 0.1 5 mg · wk 6 · n 71 · Phase 2 · secondary NCT02390050
  • -0.6 vs -0.1 5 mg · wk 2 · n 71 · Phase 2 · secondary NCT02390050
Dapagliflozin
-1.3 vs 0.2−1.5 vs placebowk 24 · n 222NCT00984867
34 other results
  • -1.6 vs -0.2 10 mg AM · wk 24 · n 70 · Phase 3 · secondary NCT00528372
  • -1.6 vs -0.2 10 mg PM · wk 24 · n 73 · Phase 3 · secondary NCT00528372
  • -1.9 vs -0.0 10 mg · wk 24 · n 108 · Phase 3 · secondary NCT01392677
  • -1.2 vs 0.2 10mg · wk 24 · n 183 · Phase 3 · secondary NCT00673231
  • -1.0 vs 0.2 5mg · wk 24 · n 204 · Phase 3 · secondary NCT00673231
  • 0.1 vs 1.0 10 mg · wk 12 · n 23 · Phase 2/3 · secondary NCT00357370
  • -0.9 vs -0.1 10 mg AM · wk 1 · n 65 · Phase 3 · secondary NCT00528372
  • -0.7 vs 0.2 2.5mg · wk 24 · n 190 · Phase 3 · secondary NCT00673231
  • -1.1 vs -0.1 10 mg PM · wk 1 · n 60 · Phase 3 · secondary NCT00528372
  • -0.5 vs 1.0 20 mg · wk 12 · n 23 · Phase 2/3 · secondary NCT00357370
  • -1.3 vs -0.2 5 mg AM · wk 24 · n 64 · Phase 3 · secondary NCT00528372
  • -1.5 vs -0.2 5 mg PM · wk 24 · n 66 · Phase 3 · secondary NCT00528372
  • -0.9 vs -0.1 5 mg AM · wk 1 · n 56 · Phase 3 · secondary NCT00528372
  • -1.0 vs -0.1 5 mg PM · wk 1 · n 54 · Phase 3 · secondary NCT00528372
  • -0.8 vs -0.2 2.5 mg AM · wk 24 · n 65 · Phase 3 · secondary NCT00528372
  • -1.4 vs -0.2 2.5 mg PM · wk 24 · n 67 · Phase 3 · secondary NCT00528372
  • -0.2 vs -0.1 2.5 mg AM · wk 1 · n 57 · Phase 3 · secondary NCT00528372
  • -1.6 vs -0.1 10 mg · wk 24 · n 150 · Phase 3 · secondary NCT00680745
  • -0.8 vs -0.1 2.5 mg PM · wk 1 · n 48 · Phase 3 · secondary NCT00528372
  • -1.3 vs -0.3 10 mg · wk 24 · n 132 · Phase 3 · secondary NCT00528879
  • -1.6 vs -0.3 10MG · wk 24 · n 140 · Phase 3 · secondary NCT00683878
  • -0.9 vs 0.1 10 mg · wk 1 · n 115 · Phase 3 · secondary NCT00528879
  • -1.2 vs -0.3 5 mg · wk 24 · n 136 · Phase 3 · secondary NCT00528879
  • -1.2 vs -0.1 5 mg · wk 24 · n 142 · Phase 3 · secondary NCT00680745
  • -1.4 vs -0.3 5MG · wk 24 · n 140 · Phase 3 · secondary NCT00683878
  • -0.7 vs 0.1 5 mg · wk 1 · n 121 · Phase 3 · secondary NCT00528879
  • -1.0 vs -0.3 2.5 mg · wk 24 · n 137 · Phase 3 · secondary NCT00528879
  • -0.9 vs -0.1 2.5 mg · wk 24 · n 154 · Phase 3 · secondary NCT00680745
  • -0.3 vs 0.1 2.5 mg · wk 1 · n 120 · Phase 3 · secondary NCT00528879
  • -0.6 vs 0.5 wk 26 · n 75 · Phase 3 · secondary NCT03199053
  • -2.3 vs -1.9 5 mg · wk 24 · n 203 · Phase 3 · secondary NCT00643851
  • -3.4 vs -1.9 wk 24 · n 192 · Phase 3 · secondary NCT00643851
  • -3.4 vs -1.9 wk 24 · n 209 · Phase 3 · secondary NCT00859898
  • -2.6 vs -1.9 wk 24 · n 216 · Phase 3 · secondary NCT00859898

3-point MACE (% with event)

Bexagliflozin
—Not reported
Dapagliflozin
—Not posted · NCT04170998
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
3 other shared endpoints and safety

Coverage. Bexagliflozin: 7 of 7 rows · Dapagliflozin: 7 of 7 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricBexagliflozin
Rows use multiple source trials
Dapagliflozin
Rows use multiple source trials
HbA1c 7.0 or Less
event count · % of participants
0.26% (n=158) vs 0.06% (n=159) placebo @ 12wk20 mga,b,c
NCT03259789 · Phase 3 · Type 2 Diabetes · phase 3
3 other source trials
22.2% (n=72) vs 15.3% (n=72) placebo @ 12wk*10 mg
NCT02390050 · Phase 2 · registry result, not featured evidence · converted to % from 16 Participants as posted
36% (n=75) vs 15.3% (n=72) placebo @ 12wk*20 mg
NCT02390050 · Phase 2 · registry result, not featured evidence · converted to % from 27 Participants as posted
21.1% (n=71) vs 15.3% (n=72) placebo @ 12wk*5 mg
NCT02390050 · Phase 2 · registry result, not featured evidence · converted to % from 15 Participants as posted
13% (n=23) vs 5.3% (n=19) placebo @ 12wk*10 mgd,a,b,c
NCT00357370 · Phase 2/3 · monotherapy · Type 2 Diabetes · phase 2/3 · converted to % from 3 Participants as posted
show 1 more dose
4.3% (n=23) vs 5.3% (n=19) placebo @ 12wk*20 mg
NCT00357370 · Phase 2/3 · monotherapy · Type 2 Diabetes · phase 2/3 · converted to % from 1 Participants as posted
SBP
absolute change · mmHg
-5.03 vs 2.04 placebo mmHg @ 24wk20 mge,f,c,g
NCT03259789 · Phase 3 · Type 2 Diabetes · phase 3
2 other source trials
-4.23 vs -1.9 Sitagliptin mmHg @ 24wk
NCT03115112 · Phase 3
-10.14 vs -7.51 placebo mmHg @ 24wk20 mg
NCT02836873 · Phase 3
-2.18 vs 4.63 Glimepiride mmHg @ 52wke,f,c,g
NCT02564926 · Phase 4 · registry result, not featured evidence
Seated SBP
absolute change · mmHg
-13.48 vs -6.95 Glimepiride mmHg @ 60wkf,h,i
NCT02769481 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
-4.04 vs -0.27 placebo mmHg @ 8wk10 mgf,h,i
NCT01392677 · Phase 3 · combination
1 other source trial
-5.98 vs -5.12 placebo mmHg @ 8wk
NCT00984867 · Phase 3
Dropout rate
3.9%20 mgj
NCT02558296 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 16 more results
15.5%
NCT02769481 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
10.8%20 mg
NCT03259789 · Phase 3 · Type 2 Diabetes · phase 3
11.4%20 mg
NCT02715258 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
6.3%
NCT03115112 · Phase 3
3.2%20 mg
NCT02836873 · Phase 3
9.2%20 mg
NCT02390050 · Phase 2 · registry result, not featured evidence
5.6%10 mg
NCT02390050 · Phase 2 · registry result, not featured evidence
6.9%5 mg
NCT02390050 · Phase 2 · registry result, not featured evidence
—Study 1: Bexagliflozin Alone
NCT03296800 · Phase 1 · registry result, not featured evidence · monotherapy
—Study 1: Bexagliflozin and Probene
NCT03296800 · Phase 1 · registry result, not featured evidence · combination
—Study 2: Bexagliflozin Alone
NCT03296800 · Phase 1 · registry result, not featured evidence · monotherapy
—Study 2: Bexagliflozin and Rrifamp
NCT03296800 · Phase 1 · registry result, not featured evidence · combination
—Study 3: Bexagliflozin Alone
NCT03296800 · Phase 1 · registry result, not featured evidence · monotherapy
—Study 3: Bexagliflozin and Verapam
NCT03296800 · Phase 1 · registry result, not featured evidence · combination
—Bexagliflozin Tablet Dosed in Fast
NCT02820298 · Phase 1 · registry result, not featured evidence
—Bexagliflozin Tablet Dosed in Fed
NCT02820298 · Phase 1 · registry result, not featured evidence
18.6%10 mg AMk
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 53 more results
14.5%10 mg PM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
12.8%10 mg AM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
18.8%5 mg AM
NCT00528372 · Phase 3 · Type 2 Diabetes · phase 3
16.2%5 mg PM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
17.6%5 mg AM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
7.7%2.5 mg AM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
13.4%2.5 mg PM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
—10 mg
NCT00357370 · Phase 2/3 · monotherapy · Type 2 Diabetes · phase 2/3
0%20 mg
NCT00357370 · Phase 2/3 · monotherapy · Type 2 Diabetes · phase 2/3
14.2%Dapagliflozin
NCT00859898 · Phase 3
13.3%Dapagliflozin + Metformin XR
NCT00859898 · Phase 3 · combination
16.3%5 mg
NCT00643851 · Phase 3
8.8%Dapagliflozin 5 mg + Metformin XR
NCT00643851 · Phase 3 · combination
11.9%10 mg
NCT00528879 · Phase 3 · combination
10.9%5 mg
NCT00528879 · Phase 3 · combination
—5.0 mg
NCT00528879 · Phase 3 · combination
12.4%2.5 mg
NCT00528879 · Phase 3 · combination
20.7%
NCT00660907 · Phase 3 · combination
6.6%10 mg
NCT00680745 · Phase 3 · combination
9%5 mg
NCT00680745 · Phase 3 · combination
9.1%2.5 mg
NCT00680745 · Phase 3 · combination
7.3%10 mg
NCT01392677 · Phase 3 · combination
10%10MG
NCT00683878 · Phase 3 · combination
11.3%5MG
NCT00683878 · Phase 3 · combination
7.6%
NCT00984867 · Phase 3
9.2%10mg
NCT00673231 · Phase 3
12.3%5mg
NCT00673231 · Phase 3
10.9%2.5mg
NCT00673231 · Phase 3
2.5%10mg QD
NCT02413398 · Phase 3
—10 mg
NCT03199053 · Phase 3
—10 mg
NCT03199053 · Phase 3
—10 mg
NCT03199053 · Phase 3 · combination
—5 mg
NCT03199053 · Phase 3
—5 mg
NCT03199053 · Phase 3
—5 mg
NCT03199053 · Phase 3
6.2%Dapagliflozin
NCT03199053 · Phase 3 · background therapy
1.3%10 mg
NCT01730534 · Phase 3
16.7%Dapagliflozin/Hyperfiltration
NCT02911792 · Phase 4 · registry result, not featured evidence
16.7%Dapagliflozin/Normofiltration
NCT02911792 · Phase 4 · registry result, not featured evidence
0%Normal Glucose Tolerance (NGT) on
NCT02981966 · Phase 4 · registry result, not featured evidence
0%T2DM Individuals on Dapagliflozin
NCT02981966 · Phase 4 · registry result, not featured evidence
0%Byetta / Bydureon
NCT02981069 · Phase 4 · registry result, not featured evidence
0%Byetta/Bydureon Plus Dapagliflozin
NCT02981069 · Phase 4 · registry result, not featured evidence · combination
12.9%
NCT03782259 · Phase 4 · registry result, not featured evidence
16%
NCT02235298 · Phase 4 · registry result, not featured evidence
—
NCT02796170 · Phase 4 · registry result, not featured evidence
—10mg
NCT03338855 · Phase 4 · registry result, not featured evidence
—
NCT02973477 · Phase 4 · registry result, not featured evidence
7.4%10 mg
NCT03387683 · Phase 4 · registry result, not featured evidence
7.7%
NCT02433678 · Phase 4 · registry result, not featured evidence
0%10mg Once Daily
NCT02682563 · Phase 4 · registry result, not featured evidence
8.3%
NCT03074630 · Phase 4 · registry result, not featured evidence
13.3%
NCT02564926 · Phase 4 · registry result, not featured evidence
Discontinued due to AEs
0.8%20 mgj
NCT02558296 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 16 more results
1.4%
NCT02769481 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
1.9%20 mg
NCT03259789 · Phase 3 · Type 2 Diabetes · phase 3
—20 mg
NCT02715258 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
2.6%
NCT03115112 · Phase 3
0.6%20 mg
NCT02836873 · Phase 3
—20 mg
NCT02390050 · Phase 2 · registry result, not featured evidence
—10 mg
NCT02390050 · Phase 2 · registry result, not featured evidence
—5 mg
NCT02390050 · Phase 2 · registry result, not featured evidence
—Study 1: Bexagliflozin Alone
NCT03296800 · Phase 1 · registry result, not featured evidence · monotherapy
—Study 1: Bexagliflozin and Probene
NCT03296800 · Phase 1 · registry result, not featured evidence · combination
—Study 2: Bexagliflozin Alone
NCT03296800 · Phase 1 · registry result, not featured evidence · monotherapy
—Study 2: Bexagliflozin and Rrifamp
NCT03296800 · Phase 1 · registry result, not featured evidence · combination
—Study 3: Bexagliflozin Alone
NCT03296800 · Phase 1 · registry result, not featured evidence · monotherapy
—Study 3: Bexagliflozin and Verapam
NCT03296800 · Phase 1 · registry result, not featured evidence · combination
—Bexagliflozin Tablet Dosed in Fast
NCT02820298 · Phase 1 · registry result, not featured evidence
—Bexagliflozin Tablet Dosed in Fed
NCT02820298 · Phase 1 · registry result, not featured evidence
8.6%10 mg AMk
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 53 more results
3.9%10 mg PM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
0%10 mg AM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
3.1%5 mg AM
NCT00528372 · Phase 3 · Type 2 Diabetes · phase 3
4.4%5 mg PM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
0%5 mg AM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
3.1%2.5 mg AM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
0%2.5 mg PM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
—10 mg
NCT00357370 · Phase 2/3 · monotherapy · Type 2 Diabetes · phase 2/3
—20 mg
NCT00357370 · Phase 2/3 · monotherapy · Type 2 Diabetes · phase 2/3
4.1%Dapagliflozin
NCT00859898 · Phase 3
1.9%Dapagliflozin + Metformin XR
NCT00859898 · Phase 3 · combination
3%5 mg
NCT00643851 · Phase 3
1%Dapagliflozin 5 mg + Metformin XR
NCT00643851 · Phase 3 · combination
3%10 mg
NCT00528879 · Phase 3 · combination
1.5%5 mg
NCT00528879 · Phase 3 · combination
—5.0 mg
NCT00528879 · Phase 3 · combination
2.9%2.5 mg
NCT00528879 · Phase 3 · combination
8.1%
NCT00660907 · Phase 3 · combination
2%10 mg
NCT00680745 · Phase 3 · combination
2.1%5 mg
NCT00680745 · Phase 3 · combination
3.2%2.5 mg
NCT00680745 · Phase 3 · combination
0.9%10 mg
NCT01392677 · Phase 3 · combination
2.1%10MG
NCT00683878 · Phase 3 · combination
2.1%5MG
NCT00683878 · Phase 3 · combination
3.1%
NCT00984867 · Phase 3
3.1%10mg
NCT00673231 · Phase 3
4.2%5mg
NCT00673231 · Phase 3
2.5%2.5mg
NCT00673231 · Phase 3
—10mg QD
NCT02413398 · Phase 3
—10 mg
NCT03199053 · Phase 3
—10 mg
NCT03199053 · Phase 3
—10 mg
NCT03199053 · Phase 3 · combination
—5 mg
NCT03199053 · Phase 3
—5 mg
NCT03199053 · Phase 3
—5 mg
NCT03199053 · Phase 3
—Dapagliflozin
NCT03199053 · Phase 3 · background therapy
—10 mg
NCT01730534 · Phase 3
—Dapagliflozin/Hyperfiltration
NCT02911792 · Phase 4 · registry result, not featured evidence
—Dapagliflozin/Normofiltration
NCT02911792 · Phase 4 · registry result, not featured evidence
—Normal Glucose Tolerance (NGT) on
NCT02981966 · Phase 4 · registry result, not featured evidence
—T2DM Individuals on Dapagliflozin
NCT02981966 · Phase 4 · registry result, not featured evidence
—Byetta / Bydureon
NCT02981069 · Phase 4 · registry result, not featured evidence
—Byetta/Bydureon Plus Dapagliflozin
NCT02981069 · Phase 4 · registry result, not featured evidence · combination
—
NCT03782259 · Phase 4 · registry result, not featured evidence
4%
NCT02235298 · Phase 4 · registry result, not featured evidence
—
NCT02796170 · Phase 4 · registry result, not featured evidence
—10mg
NCT03338855 · Phase 4 · registry result, not featured evidence
—
NCT02973477 · Phase 4 · registry result, not featured evidence
—10 mg
NCT03387683 · Phase 4 · registry result, not featured evidence
—
NCT02433678 · Phase 4 · registry result, not featured evidence
—10mg Once Daily
NCT02682563 · Phase 4 · registry result, not featured evidence
—
NCT03074630 · Phase 4 · registry result, not featured evidence
—
NCT02564926 · Phase 4 · registry result, not featured evidence
Serious AEs
33%20 mgj
NCT02558296 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 16 more results
11.7%
NCT02769481 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
1.9%20 mg
NCT03259789 · Phase 3 · Type 2 Diabetes · phase 3
0.7%20 mg
NCT02715258 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
3.7%
NCT03115112 · Phase 3
7%20 mg
NCT02836873 · Phase 3
2.6%20 mg
NCT02390050 · Phase 2 · registry result, not featured evidence
4.2%10 mg
NCT02390050 · Phase 2 · registry result, not featured evidence
0%5 mg
NCT02390050 · Phase 2 · registry result, not featured evidence
0%Study 1: Bexagliflozin Alone
NCT03296800 · Phase 1 · registry result, not featured evidence · monotherapy
0%Study 1: Bexagliflozin and Probene
NCT03296800 · Phase 1 · registry result, not featured evidence · combination
0%Study 2: Bexagliflozin Alone
NCT03296800 · Phase 1 · registry result, not featured evidence · monotherapy
0%Study 2: Bexagliflozin and Rrifamp
NCT03296800 · Phase 1 · registry result, not featured evidence · combination
0%Study 3: Bexagliflozin Alone
NCT03296800 · Phase 1 · registry result, not featured evidence · monotherapy
0%Study 3: Bexagliflozin and Verapam
NCT03296800 · Phase 1 · registry result, not featured evidence · combination
0%Bexagliflozin Tablet Dosed in Fast
NCT02820298 · Phase 1 · registry result, not featured evidence
0%Bexagliflozin Tablet Dosed in Fed
NCT02820298 · Phase 1 · registry result, not featured evidence
1.4%10 mg AMk
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 53 more results
3.9%10 mg PM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
—10 mg AM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
6.3%5 mg AM
NCT00528372 · Phase 3 · Type 2 Diabetes · phase 3
7.4%5 mg PM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
—5 mg AM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
9.2%2.5 mg AM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
10.4%2.5 mg PM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
0%10 mg
NCT00357370 · Phase 2/3 · monotherapy · Type 2 Diabetes · phase 2/3
4.2%20 mg
NCT00357370 · Phase 2/3 · monotherapy · Type 2 Diabetes · phase 2/3
2.3%Dapagliflozin
NCT00859898 · Phase 3
1.4%Dapagliflozin + Metformin XR
NCT00859898 · Phase 3 · combination
4.4%5 mg
NCT00643851 · Phase 3
3.1%Dapagliflozin 5 mg + Metformin XR
NCT00643851 · Phase 3 · combination
10.4%10 mg
NCT00528879 · Phase 3 · combination
—5 mg
NCT00528879 · Phase 3 · combination
6.6%5.0 mg
NCT00528879 · Phase 3 · combination
10.9%2.5 mg
NCT00528879 · Phase 3 · combination
8.6%
NCT00660907 · Phase 3 · combination
6%10 mg
NCT00680745 · Phase 3 · combination
6.9%5 mg
NCT00680745 · Phase 3 · combination
7.1%2.5 mg
NCT00680745 · Phase 3 · combination
0.9%10 mg
NCT01392677 · Phase 3 · combination
1.4%10MG
NCT00683878 · Phase 3 · combination
2.8%5MG
NCT00683878 · Phase 3 · combination
4.4%
NCT00984867 · Phase 3
7.1%10mg
NCT00673231 · Phase 3
4.7%5mg
NCT00673231 · Phase 3
7.4%2.5mg
NCT00673231 · Phase 3
5.6%10mg QD
NCT02413398 · Phase 3
0%10 mg
NCT03199053 · Phase 3
4.8%10 mg
NCT03199053 · Phase 3
0%10 mg
NCT03199053 · Phase 3 · combination
1.2%5 mg
NCT03199053 · Phase 3
0%5 mg
NCT03199053 · Phase 3
9.1%5 mg
NCT03199053 · Phase 3
—Dapagliflozin
NCT03199053 · Phase 3 · background therapy
37.4%10 mg
NCT01730534 · Phase 3
0%Dapagliflozin/Hyperfiltration
NCT02911792 · Phase 4 · registry result, not featured evidence
0%Dapagliflozin/Normofiltration
NCT02911792 · Phase 4 · registry result, not featured evidence
0%Normal Glucose Tolerance (NGT) on
NCT02981966 · Phase 4 · registry result, not featured evidence
0%T2DM Individuals on Dapagliflozin
NCT02981966 · Phase 4 · registry result, not featured evidence
0%Byetta / Bydureon
NCT02981069 · Phase 4 · registry result, not featured evidence
0%Byetta/Bydureon Plus Dapagliflozin
NCT02981069 · Phase 4 · registry result, not featured evidence · combination
—
NCT03782259 · Phase 4 · registry result, not featured evidence
0%
NCT02235298 · Phase 4 · registry result, not featured evidence
0%
NCT02796170 · Phase 4 · registry result, not featured evidence
0%10mg
NCT03338855 · Phase 4 · registry result, not featured evidence
2.3%
NCT02973477 · Phase 4 · registry result, not featured evidence
0%10 mg
NCT03387683 · Phase 4 · registry result, not featured evidence
0%
NCT02433678 · Phase 4 · registry result, not featured evidence
0%10mg Once Daily
NCT02682563 · Phase 4 · registry result, not featured evidence
—
NCT03074630 · Phase 4 · registry result, not featured evidence
10%
NCT02564926 · Phase 4 · registry result, not featured evidence
Most frequent reported AEs
20 mgj
hypoglycaemia 42% (placebo 43.4%)
urinary tract infection 11.3% (placebo 10.6%)
upper respiratory tract infection 9.9% (placebo 9.3%)
NCT02558296 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 16 more results
hypoglycemia 16.9%
nasopharyngitis 13.6%
urinary tract infection 11.7%
NCT02769481 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
20 mg
nasopharyngitis 5.7% (placebo 8.2%)
polydipsia 3.2% (placebo 2.5%)
polyuria 3.2% (placebo 3.8%)
NCT03259789 · Phase 3 · Type 2 Diabetes · phase 3
20 mg
polyuria 7.2% (placebo 2.9%)
urinary tract infection 5.1% (placebo 2.9%)
abdominal pain 3.6% (placebo 7.2%)
NCT02715258 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
nasopharyngitis 7.9%
urinary tract infection 3.7%
hypoglycemia 3.1%
NCT03115112 · Phase 3
20 mg
hypoglycaemia 25.5% (placebo 25.8%)
polyuria 7.6% (placebo 4.5%)
nasopharyngitis 7% (placebo 8.4%)
NCT02836873 · Phase 3
20 mg
hypoglycemia 5.3% (placebo 1.4%)
dysuria 3.9% (placebo 1.4%)
nasopharyngitis 3.9% (placebo 4.2%)
NCT02390050 · Phase 2 · registry result, not featured evidence
10 mg
nasopharyngitis 5.6% (placebo 4.2%)
pharyngitis 4.2% (placebo 0%)
arthralgia 2.8% (placebo 0%)
NCT02390050 · Phase 2 · registry result, not featured evidence
5 mg
nasopharyngitis 6.9% (placebo 4.2%)
diarrhea 2.8% (placebo 2.8%)
dizziness 2.8% (placebo 1.4%)
NCT02390050 · Phase 2 · registry result, not featured evidence
diarrhea 0%
gastrointestinal sounds abnormal 0%
laceration 0%
NCT03296800 · Phase 1 · registry result, not featured evidence · monotherapy
diarrhea 6.3%
gastrointestinal sounds abnormal 6.3%
laceration 0%
NCT03296800 · Phase 1 · registry result, not featured evidence · combination
diarrhea 0%
gastrointestinal sounds abnormal 0%
laceration 0%
NCT03296800 · Phase 1 · registry result, not featured evidence · monotherapy
diarrhea 0%
gastrointestinal sounds abnormal 0%
laceration 0%
NCT03296800 · Phase 1 · registry result, not featured evidence · combination
laceration 6.3%
presyncope 6.3%
diarrhea 0%
NCT03296800 · Phase 1 · registry result, not featured evidence · monotherapy
diarrhea 0%
gastrointestinal sounds abnormal 0%
laceration 0%
NCT03296800 · Phase 1 · registry result, not featured evidence · combination
dizziness 4.2%
headache 4.2%
nasal congestion 4.2%
NCT02820298 · Phase 1 · registry result, not featured evidence
chest discomfort 4.3%
dizziness 4.3%
headache 4.3%
NCT02820298 · Phase 1 · registry result, not featured evidence
10 mg AMk
nasopharyngitis 14.3% (placebo 9.3%)
arthralgia 8.6% (placebo 4%)
headache 8.6% (placebo 12%)
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 42 more results
10 mg PM
headache 13.2% (placebo 12%)
upper respiratory tract infection 11.8% (placebo 5.3%)
back pain 9.2% (placebo 6.7%)
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
5 mg AM
pharyngitis 9.4% (placebo 8%)
arthralgia 7.8% (placebo 4%)
headache 7.8% (placebo 12%)
NCT00528372 · Phase 3 · Type 2 Diabetes · phase 3
5 mg PM
headache 16.2% (placebo 12%)
nasopharyngitis 13.2% (placebo 9.3%)
arthralgia 11.8% (placebo 4%)
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
2.5 mg AM
nasopharyngitis 16.9% (placebo 9.3%)
influenza 10.8% (placebo 4%)
arthralgia 9.2% (placebo 4%)
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
2.5 mg PM
nasopharyngitis 16.4% (placebo 9.3%)
abdominal pain 9% (placebo 2.7%)
dizziness 9% (placebo 2.7%)
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
10 mg
back pain 12.5% (placebo 8.7%)
headache 12.5% (placebo 8.7%)
fatigue 8.3% (placebo 0%)
NCT00357370 · Phase 2/3 · monotherapy · Type 2 Diabetes · phase 2/3
20 mg
nausea 12.5% (placebo 4.3%)
pollakiuria 12.5% (placebo 17.4%)
vomiting 12.5% (placebo 0%)
NCT00357370 · Phase 2/3 · monotherapy · Type 2 Diabetes · phase 2/3
urinary tract infection 7.8%
vulvovaginal mycotic infection 5%
diarrhoea 2.7%
NCT00859898 · Phase 3
diarrhoea 7.1%
vulvovaginal mycotic infection 3.3%
urinary tract infection 2.8%
NCT00859898 · Phase 3 · combination
5 mg
dyslipidaemia 5.4%
upper respiratory tract infection 4.9%
urinary tract infection 4.4%
NCT00643851 · Phase 3
diarrhoea 7.7%
nausea 5.7%
upper respiratory tract infection 5.2%
NCT00643851 · Phase 3 · combination
10 mg
back pain 13.3% (placebo 8%)
influenza 12.6% (placebo 10.9%)
diarrhoea 11.9% (placebo 7.3%)
NCT00528879 · Phase 3 · combination
5.0 mg
influenza 14.6% (placebo 10.9%)
headache 9.5% (placebo 5.8%)
arthralgia 7.3% (placebo 5.1%)
NCT00528879 · Phase 3 · combination
2.5 mg
influenza 13.9% (placebo 10.9%)
nasopharyngitis 11.7% (placebo 8.8%)
back pain 8% (placebo 8%)
NCT00528879 · Phase 3 · combination
nasopharyngitis 10.6%
hypertension 7.4%
influenza 7.4%
NCT00660907 · Phase 3 · combination
10 mg
hypoglycemia 7.9% (placebo 4.8%)
nasopharyngitis 3.3% (placebo 2.7%)
hypertension 1.3% (placebo 4.1%)
NCT00680745 · Phase 3 · combination
5 mg
hypoglycemia 6.9% (placebo 4.8%)
nasopharyngitis 5.5% (placebo 2.7%)
hypertension 1.4% (placebo 4.1%)
NCT00680745 · Phase 3 · combination
2.5 mg
hypoglycemia 7.1% (placebo 4.8%)
hypertension 5.2% (placebo 4.1%)
nasopharyngitis 1.9% (placebo 2.7%)
NCT00680745 · Phase 3 · combination
10 mg
urinary tract infection 4.6% (placebo 6.4%)
NCT01392677 · Phase 3 · combination
10MG
dyslipidaemia 9.3% (placebo 4.3%)
nasopharyngitis 7.9% (placebo 3.6%)
diarrhoea 6.4% (placebo 4.3%)
NCT00683878 · Phase 3 · combination
5MG
upper respiratory tract infection 6.4% (placebo 5.8%)
dyslipidaemia 5.7% (placebo 4.3%)
nasopharyngitis 5% (placebo 3.6%)
NCT00683878 · Phase 3 · combination
nasopharyngitis 4% (placebo 6.2%)
NCT00984867 · Phase 3
10mg
hypoglycemia 44.9% (placebo 42.1%)
nasopharyngitis 8.7% (placebo 11.2%)
urinary tract infection 5.6% (placebo 3%)
NCT00673231 · Phase 3
5mg
hypoglycemia 47.6% (placebo 42.1%)
nasopharyngitis 13.7% (placebo 11.2%)
hypertension 6.1% (placebo 8.1%)
NCT00673231 · Phase 3
2.5mg
hypoglycemia 55% (placebo 42.1%)
nasopharyngitis 13.9% (placebo 11.2%)
hypertension 5.4% (placebo 8.1%)
NCT00673231 · Phase 3
10 mg
abdominal pain 4.8% (placebo 2.6%)
abdominal pain upper 4.8% (placebo 0%)
bronchitis 4.8% (placebo 0%)
NCT03199053 · Phase 3
10 mg
dysmenorrhoea 9.5% (placebo 2.6%)
headache 9.5% (placebo 1.3%)
conjunctivitis allergic 4.8% (placebo 0%)
NCT03199053 · Phase 3
10 mg
pharyngotonsillitis 14.3% (placebo 1.3%)
tonsillitis 14.3% (placebo 0%)
abdominal pain 0% (placebo 2.6%)
NCT03199053 · Phase 3 · combination
5 mg
headache 7.4% (placebo 1.3%)
hypertriglyceridaemia 4.9% (placebo 1.3%)
diarrhoea 3.7% (placebo 3.9%)
NCT03199053 · Phase 3
5 mg
headache 9.1% (placebo 1.3%)
nasopharyngitis 3.6% (placebo 2.6%)
anxiety 1.8% (placebo 0%)
NCT03199053 · Phase 3
5 mg
influenza 5.5% (placebo 2.6%)
abdominal pain upper 3.6% (placebo 0%)
headache 3.6% (placebo 1.3%)
NCT03199053 · Phase 3
10 mg
renal impairment 1.4% (placebo 1.7%)
acute kidney injury 1% (placebo 1.3%)
chronic kidney disease 0.9% (placebo 1.2%)
NCT01730534 · Phase 3
genital mycotic infection 13.3%
mild hypoglycemia 0%
NCT02911792 · Phase 4 · registry result, not featured evidence
genital mycotic infection 26.7%
mild hypoglycemia 0%
NCT02911792 · Phase 4 · registry result, not featured evidence
transcient syncope 12.5% (placebo 0%)
NCT02981966 · Phase 4 · registry result, not featured evidence
transcient syncope 0% (placebo 0%)
NCT02981966 · Phase 4 · registry result, not featured evidence
nausea and vomiting 24% (placebo 0%)
genital mycosis 0% (placebo 0%)
NCT02981069 · Phase 4 · registry result, not featured evidence
nausea and vomiting 20% (placebo 0%)
genital mycosis 8% (placebo 0%)
NCT02981069 · Phase 4 · registry result, not featured evidence · combination
dysuria 12% (placebo 0%)
frequency of urination 12% (placebo 0%)
balanitis 2% (placebo 0%)
NCT02235298 · Phase 4 · registry result, not featured evidence
cold like symptoms 4.5%
genital yeast infection 4.5%
abrasion of left cornea 2.3%
NCT02973477 · Phase 4 · registry result, not featured evidence
10mg Once Daily
genital fungal infections 20.8%
NCT02682563 · Phase 4 · registry result, not featured evidence
nasopharyngitis 6.7%
toothache 6.7%
hypoglycaemia 5%
NCT02564926 · Phase 4 · registry result, not featured evidence

Notes

  1. aTrial phases differ: Phase 2/3 versus Phase 3.
  2. bPopulation context differs: baseline_threshold differs (bmi<=45 versus bmi<=45, hba1c<=10.5, hba1c>=7.5); prior_therapy differs (none recorded versus experienced).
  3. cTreatment context has not been resolved for both arms.
  4. dThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  5. eTrial phases differ: Phase 4 versus Phase 3.
  6. fPopulation comparability has not been reviewed for both studies.
  7. gAssessment timepoints differ: 52 weeks versus 24 weeks.
  8. hTreatment context differs: combination versus monotherapy.
  9. iAssessment timepoints differ: 8 weeks versus 60 weeks.
  10. jPopulation comparability has not been reviewed for 13 of these studies.
  11. kPopulation comparability has not been reviewed for 44 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Dapagliflozin

Fasting Plasma Glucose -4.68 mmol/L @ 24wk10 mg AM
absolute change · mmol/L
No placebo or comparator arm
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to mmol/L from -84.3 mg/dL as posted
show 5 more results
-4.12 mmol/L @ 1wk*10 mg AM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to mmol/L from -74.3 mg/dL as posted
-1.62 mmol/L @ 26wk10 mg
NCT03199053 · Phase 3
-4.27 mmol/L @ 24wk*5 mg AM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to mmol/L from -77 mg/dL as posted
-3.01 mmol/L @ 1wk*5 mg AM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to mmol/L from -54.3 mg/dL as posted
-0.98 mmol/L @ 26wk5 mg
NCT03199053 · Phase 3
Weight -1.9 kg @ 24wk10 mg AM
absolute change · kg
No placebo or comparator arm
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 1 more result
-2.06 kg @ 24wk5 mg AM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
HbA1c Less Than 7% 50.8% (n=65) vs 31.6% (n=72) placebo @ 24wk10 mg AM
responder rate · % of participants
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 17 more results
51.6% (n=73) vs 31.6% (n=72) placebo @ 24wk10 mg PM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
31.8% (n=108) vs 11.1% (n=108) placebo @ 24wk10 mg
NCT01392677 · Phase 3 · combination
44.2% (n=61) vs 31.6% (n=72) placebo @ 24wk5 mg AM
NCT00528372 · Phase 3 · Type 2 Diabetes · phase 3
44% (n=63) vs 31.6% (n=72) placebo @ 24wk5 mg PM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
22.5% (n=196) vs 34.6% (n=195) Metformin XR @ 24wk5 mg
NCT00643851 · Phase 3
41.3% (n=64) vs 31.6% (n=72) placebo @ 24wk2.5 mg AM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
51.4% (n=62) vs 31.6% (n=72) placebo @ 24wk2.5 mg PM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
40.6% (n=132) vs 25.9% (n=134) placebo @ 24wk10 mg
NCT00528879 · Phase 3 · combination
31.7% (n=150) vs 13% (n=143) placebo @ 24wk10 mg
NCT00680745 · Phase 3 · combination
38.8% (n=140) vs 22.4% (n=138) placebo @ 24wk10MG
NCT00683878 · Phase 3 · combination
52.4% (n=185) vs 34.6% (n=195) Metformin XR @ 24wk
NCT00643851 · Phase 3 · combination
37.5% (n=133) vs 25.9% (n=134) placebo @ 24wk5 mg
NCT00528879 · Phase 3 · combination
30.3% (n=142) vs 13% (n=143) placebo @ 24wk5 mg
NCT00680745 · Phase 3 · combination
32.5% (n=140) vs 22.4% (n=138) placebo @ 24wk5MG
NCT00683878 · Phase 3 · combination
33% (n=135) vs 25.9% (n=134) placebo @ 24wk2.5 mg
NCT00528879 · Phase 3 · combination
26.8% (n=154) vs 13% (n=143) placebo @ 24wk2.5 mg
NCT00680745 · Phase 3 · combination
26.6% (n=64) vs 10% (n=50) placebo @ 26wk
NCT03199053 · Phase 3 · background therapy
HbA1c Less Than or Equal to 6.5 23.1% (n=14) vs 14.5% (n=11) placebo @ 24wk10 mg AM
responder rate · % of participants
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 8 more results
26% (n=73) vs 14.5% (n=11) placebo @ 24wk10 mg PM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
26.6% (n=17) vs 14.5% (n=11) placebo @ 24wk5 mg AM
NCT00528372 · Phase 3 · Type 2 Diabetes · phase 3
25.8% (n=63) vs 14.5% (n=11) placebo @ 24wk5 mg PM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
27.2% (n=17) vs 14.5% (n=11) placebo @ 24wk2.5 mg AM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
33.4% (n=62) vs 14.5% (n=11) placebo @ 24wk2.5 mg PM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
25.2% (n=36) vs 13.8% (n=18) placebo @ 24wk10 mg
NCT00528879 · Phase 3 · combination
14.5% (n=18) vs 13.8% (n=18) placebo @ 24wk5 mg
NCT00528879 · Phase 3 · combination
20.7% (n=29) vs 13.8% (n=18) placebo @ 24wk2.5 mg
NCT00528879 · Phase 3 · combination
HbA1c -2.66% (n=32) @ 24wk10 mg AM
absolute change · percentage points
No placebo or comparator arm
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 3 more results
-0.74% (n=19) @ 26wk10 mg
NCT03199053 · Phase 3
-2.88% (n=25) @ 24wk5 mg AM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
-0.71% (n=21) @ 26wk5 mg
NCT03199053 · Phase 3
HbA1c Less Than or Equal to 6.5 4.3% (n=23) vs 0% (n=19) placebo @ 12wk10 mg
event count · % of participants
NCT00357370 · Phase 2/3 · monotherapy · Type 2 Diabetes · phase 2/3 · converted to % from 1 Participants as posted
show 1 more result
0% (n=23) vs 0% (n=19) placebo @ 12wk*20 mg
NCT00357370 · Phase 2/3 · monotherapy · Type 2 Diabetes · phase 2/3 · converted to % from 0 Participants as posted
HbA1C Decrease at Least 0.5 65.2% (n=23) vs 15.8% (n=19) placebo @ 12wk10 mg
event count · % of participants
NCT00357370 · Phase 2/3 · monotherapy · Type 2 Diabetes · phase 2/3 · converted to % from 15 Participants as posted
show 1 more result
65.2% (n=23) vs 15.8% (n=19) placebo @ 12wk*20 mg
NCT00357370 · Phase 2/3 · monotherapy · Type 2 Diabetes · phase 2/3 · converted to % from 15 Participants as posted
TDDI Change Units Per -1.35 vs 1.69 placebo per day @ 12wk10 mg
absolute change · per day
NCT00357370 · Phase 2/3 · monotherapy · Type 2 Diabetes · phase 2/3
show 4 more results
-1.16 vs 5.08 placebo per day @ 24wk10mg
NCT00673231 · Phase 3
-0.83 vs 1.69 placebo per day @ 12wk20 mg
NCT00357370 · Phase 2/3 · monotherapy · Type 2 Diabetes · phase 2/3
-0.61 vs 5.08 placebo per day @ 24wk5mg
NCT00673231 · Phase 3
-1.8 vs 5.08 placebo per day @ 24wk2.5mg
NCT00673231 · Phase 3
HbA1c Less Than 7 46.6% (n=202) vs 35.5% (n=203) Metformin XR @ 24wk
absolute value · percentage points
NCT00859898 · Phase 3 · combination
show 1 more result
31.7% (n=216) vs 35.5% (n=203) Metformin XR @ 24wk
NCT00859898 · Phase 3
Weight Loss 5% 33.3% (n=400) vs 2.5% (n=401) Glipizide Plus Metformin @ 52wk
responder rate · % of participants
NCT00660907 · Phase 3 · combination
OGTT 2 h Change mg/dL -34.9 vs -6 placebo mg/dL @ 24wk10 mg
absolute change · mg/dL
NCT00680745 · Phase 3 · combination
show 2 more results
-32 vs -6 placebo mg/dL @ 24wk5 mg
NCT00680745 · Phase 3 · combination
-37.5 vs -6 placebo mg/dL @ 24wk2.5 mg
NCT00680745 · Phase 3 · combination
PPG 2h Change mg/dL -3.75 vs -0.78 placebo mmol/L @ 24wk10MG
absolute change · mmol/L
NCT00683878 · Phase 3 · combination · converted to mmol/L from -67.5 mg/dL as posted
show 2 more results
-3.61 vs -0.78 placebo mmol/L @ 24wk*5MG
NCT00683878 · Phase 3 · combination · converted to mmol/L from -65.1 mg/dL as posted
-1.2 vs -0.38 placebo mmol/L @ 24wk*
NCT00984867 · Phase 3 · converted to mmol/L from -21.65 mg/dL as posted

+ 35 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Bexagliflozin's landscape · Dapagliflozin's landscape